Intercept receives orphan drug designation for liver disease combo therapy
Pharmaceutical Technology
MAY 17, 2023
The US Food and Drug Administration (FDA) has awarded an orphan drug designation to Intercept Pharmaceuticals’ fixed-dose combination of obeticholic acid and bezafibrate for the treatment of primary biliary cholangitis. This results in bile buildup in the liver and can lead to scarring. billion in 2029.
Let's personalize your content